Publication Name	World Journal of Hematology
Manuscript ID	7322
Country	Taiwan

Received	2013-11-13 08:45
Peer-Review Started	2013-11-14 11:34
To Make the First Decision	2013-12-25 18:05
Return for Revision	2013-12-31 14:50
Revised	2014-01-27 23:22
Second Decision	2014-03-18 15:00
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-03-18 15:24
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-05-08 20:26
Publish the Manuscript Online	2014-05-20 16:06

ISSN	2218-6204 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Hematology
Manuscript Type	Review
Article Title	Anti-CD20 monoclonal antibodies and associated viral hepatitis in hematological diseases
Manuscript Source	Invited Manuscript
All Author List	Shih-Hung Yang, Chiun Hsu, Ann-Lii Cheng and Sung-Hsin Kuo
Funding Agency and Grant Number	Funding Agency Grant Number NSC 101-2321-B-002-032 NSC 101-2314-B-002-157-MY3 National Health Research Institutes, Taiwan NHRI-EX102-10239BI Department of Health, Taiwan DOH100-TD-B-111-001
Corresponding Author	Sung-Hsin Kuo, MD, PhD, Department of Oncology, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 100, Taiwan. shkuo101@ntu.edu.tw
Key Words	CD20; Monoclonal antibody; Hepatitis; Hepatitis B virus; Hepatitis C virus
Core Tip	Anti-CD20 monoclonal antibodies are widely used for the treatment of hematological malignancies and autoimmune disorders. These agents produce prolonged B-cell depletion and significant immune suppression. In this review, we summarized the clinical use of anti-CD20 monoclonal antibodies and the reports of acute or chronic hepatitis associated with the use of these agents. Most of these hepatitis cases had viral etiologies. We discuss the mechanisms of the hepatitis caused by these drugs. These infections not only interrupted the immunotherapy but are also associated with high mortality and morbidity. This review may prompt physicians to monitor patients’ liver function more closely and to provide adequate prophylaxis while using these agents.
Publish Date	2014-05-20 16:06
Citation	Yang SH, Hsu C, Cheng AL, Kuo SH. Anti-CD20 monoclonal antibodies and associated viral hepatitis in hematological diseases. World J Hematol 2014; 3(2): 29-43
URL	http://www.wjgnet.com/2218-6204/full/v3/i2/29.htm
DOI	http://dx.doi.org/10.5315/wjh.v3.i2.29

Full Article (PDF)	WJH-3-29.pdf
Full Article (Word)	WJH-3-29.doc
Manuscript File	7322-Review.doc
Answering Reviewers	7322-Answering reviewers.pdf
Copyright License Agreement	7322-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	7322-Language certificate.pdf
Peer-review Report	7322-Peer reviews.pdf
Scientific Editor Work List	7322-Scientific editor work list.doc